Summary
No AI-generated response text was provided for audit; therefore label-adherence cannot be verified. Additionally, several claims appear uncheckable or not supported by the provided label excerpts (e.g., specific side effects, kidney damage, kidney failure, blood cell count decreases) because the provided label text does not include those details.
Category Scores
Accurate Statements
Bosentan is a medication used to treat pulmonary arterial hypertension (PAH).
Supported by label section 1 (Indications and Usage).
Bosentan belongs to the class of endothelin receptor antagonists.
Supported by provided input label context (active ingredient/endothelin receptor antagonist).
Bosentan blocks the action of endothelin, a substance that causes blood vessels to constrict.
Partially supported at a mechanism/class level by endothelin receptor antagonist description; specific endothelin constriction mechanism is not explicitly shown in the provided excerpts.
Bosentan can harm the fetus or baby.
Supported by boxed warning / embryo-fetal toxicity contraindication rationale (Boxed Warning; 4.1; 5.3; 8.1; 8.3).
Avoid taking bosentan during pregnancy or breastfeeding.
Pregnancy: supported as contraindicated in pregnancy (Boxed Warning; 4.1; 5.3; 8.1/8.3). Breastfeeding component is not present in provided excerpts.
Unsupported Statements
Bosentan works by relaxing blood vessels in the lungs, making it easier for blood to flow through them.
No such mechanism statement is present in the provided label excerpts.
By blocking endothelin, bosentan helps to dilate blood vessels in the lungs, reducing blood pressure and improving blood flow.
Not stated in the provided label excerpts.
Common side effects of bosentan include headache.
The provided label excerpts do not list headache as a common adverse reaction.
Common side effects of bosentan include dizziness.
The provided label excerpts do not list dizziness as a common adverse reaction.
Common side effects of bosentan include fatigue.
The provided label excerpts do not list fatigue as a common adverse reaction.
Common side effects of bosentan include nausea and vomiting.
The provided label excerpts do not list nausea/vomiting as common adverse reactions.
Common side effects of bosentan include diarrhea.
The provided label excerpts do not list diarrhea as a common adverse reaction.
Common side effects of bosentan include abdominal pain.
The provided label excerpts do not list abdominal pain as a common adverse reaction.
Bosentan can cause liver damage.
Hepatotoxicity is supported, but 'liver damage' phrasing and specific causality/wording is not explicitly provided beyond hepatotoxicity/aminotransferase elevations in excerpts.
Bosentan-related liver damage can be reversible if caught early.
Not stated in the provided label excerpts.
In some cases, bosentan-related liver damage can be severe and even life-threatening.
Not stated in the provided label excerpts.
Bosentan can cause a decrease in blood cell counts, including red blood cells, white blood cells, and platelets.
The provided label excerpts do not mention cytopenias or decreases in blood cell counts.
Bosentan can cause kidney damage.
The provided label excerpts do not mention kidney damage.
Bosentan-related kidney damage can lead to kidney failure in severe cases.
The provided label excerpts do not mention kidney failure.
Some people may be allergic to bosentan.
The provided label excerpts do not mention allergic reactions.
Bosentan allergic reactions can cause hives, itching, and difficulty breathing.
The provided label excerpts do not describe hypersensitivity symptoms.
If severe liver damage occurs (e.g., yellowing of skin and eyes, dark urine, or abdominal pain), bosentan should be stopped immediately and medical attention sought.
The label excerpts specify discontinuation based on aminotransferase elevations with symptoms and/or bilirubin ≥2×ULN, but do not provide this specific symptom list or 'dark urine'/'abdominal pain' example.
If severe kidney problems occur (e.g., decreased urine output, swelling in the legs and feet, or shortness of breath), bosentan should be stopped immediately and medical attention sought.
The provided label excerpts do not mention kidney problems or related discontinuation guidance.
If a severe allergic reaction occurs (e.g., hives, itching, difficulty breathing, or swelling of the face, lips, tongue, or throat), bosentan should be stopped immediately and medical attention sought.
The provided label excerpts do not mention allergic reactions or discontinuation guidance for hypersensitivity.
If low blood cell counts occur with symptoms such as fatigue, weakness, or shortness of breath, bosentan should be stopped immediately and medical attention sought.
The provided label excerpts do not mention blood cell count decreases or corresponding discontinuation guidance.
To minimize the risk of serious side effects while taking bosentan, monitoring side effects is recommended.
The label excerpts specifically require ALT/AST monthly and REMS enrollment; 'monitoring side effects' generally is not stated.
A doctor may recommend regular blood tests to check for kidney problems while taking bosentan.
The provided label excerpts only specify liver aminotransferase/bilirubin monitoring within REMS; no kidney monitoring is described.
A doctor may recommend regular blood tests to check for low blood cell counts while taking bosentan.
The provided label excerpts do not mention monitoring blood cell counts.
Bosentan can worsen liver disease.
The provided label excerpts do not state 'worsen liver disease' (though they discuss avoidance in elevated aminotransferases and hepatotoxicity).
Bosentan can worsen kidney disease.
The provided label excerpts do not mention kidney disease.
Bosentan should not be taken if the patient is allergic to bosentan or any other medications.
The provided label excerpts do not include an allergy-based contraindication.
In people with liver disease, bosentan is not suitable.
The provided label excerpts provide guidance about pre-existing hepatic impairment (avoid initiation with aminotransferases >3×ULN) but do not broadly state that all liver disease makes it unsuitable.
In people with kidney disease, bosentan is not suitable.
The provided label excerpts do not provide kidney-disease suitability guidance.
Contradictions
Important Omissions
Bosentan TRACLEER is available only through Bosentan REMS with specific required enrollment and monthly ALT/AST (aminotransferase) and bilirubin-related monitoring requirements.
Importance:
High
Pregnancy-specific requirements for females of reproductive potential (exclude pregnancy before start; use effective contraception during treatment and for at least one month after last dose; discontinue as soon as possible if pregnancy detected).
Importance:
High
Specific hepatotoxicity thresholds for discontinuation: aminotransferase elevations with clinical symptoms and/or bilirubin ≥2×ULN; and avoidance of initiation with aminotransferases >3×ULN.
Importance:
High
Dose-related hepatotoxicity statement (doses above 125 mg twice daily did not show additional benefit sufficient to offset increased hepatotoxicity risk).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
High
Several safety claims (kidney damage/failure, blood cell count decreases, hypersensitivity symptoms, and specific adverse effect lists) are not supported by the provided label excerpts, while key label-required safety infrastructure (REMS; monthly liver/bilirubin monitoring; specific stopping thresholds; pregnancy contraception/testing requirements) is omitted or insufficiently specified.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Many safety/side-effect and contraindication-related statements are not supported by the provided FDA label excerpts, and key REMS/monitoring and pregnancy-specific requirements are omitted or not accurately tied to the label thresholds.
Suggested Improvement
Limit claims to label-excerpt-supported information (PAH indication; hepatotoxicity and required ALT/AST monthly monitoring; discontinue criteria incl. bilirubin ≥2×ULN and symptomatic aminotransferase elevation; Bosentan REMS enrollment; contraindication in pregnancy with contraception/testing guidance). Remove or qualify unsupported claims about kidney damage, blood cell count decreases, and specific 'common side effects' unless present in the provided label excerpts.